Harvard Bioscience Inc
NASDAQ:HBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Harvard Bioscience Inc
Total Equity
Harvard Bioscience Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Harvard Bioscience Inc
NASDAQ:HBIO
|
Total Equity
$13.7m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-16%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Total Equity
$53.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Danaher Corp
NYSE:DHR
|
Total Equity
$52.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Waters Corp
NYSE:WAT
|
Total Equity
$2.6B
|
CAGR 3-Years
72%
|
CAGR 5-Years
62%
|
CAGR 10-Years
2%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Total Equity
$6.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Total Equity
$6.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Harvard Bioscience Inc
Glance View
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company is headquartered in Holliston, Massachusetts and currently employs 475 full-time employees. The company went IPO on 2013-10-21. The firm provides products that support research in six different classes of laboratory use, including molecular, cellular, tissue, organ, organisms or preclinical, and clinical. The firm organizes its product line activities into two product families, Cellular and Molecular Technologies (CMT) and Preclinical. The company primarily sells its products under several brand names, including Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The firm's customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs, and government researchers.
See Also
What is Harvard Bioscience Inc's Total Equity?
Total Equity
13.7m
USD
Based on the financial report for Dec 31, 2025, Harvard Bioscience Inc's Total Equity amounts to 13.7m USD.
What is Harvard Bioscience Inc's Total Equity growth rate?
Total Equity CAGR 10Y
-16%
Over the last year, the Total Equity growth was -78%. The average annual Total Equity growth rates for Harvard Bioscience Inc have been -42% over the past three years , -29% over the past five years , and -16% over the past ten years .
